

Draft Agenda

54th meeting of the Member State Committee

12-16 June 2017
ECHA Conference Centre
Annankatu 18, in Helsinki, Finland

12 June: starts at 9 am
16 June: ends at 1 pm

Item 1 – Welcome and Apologies

Item 2 – Adoption of the Agenda

MSC/A/054/2017
For adoption

Item 3 – Declarations of conflicts of interest to items on the Agenda

Item 4 – Administrative issues

- Outlook for MSC-55
- Outlook for MSC-57

For information

Item 5 – Minutes of the MSC-53

- Draft minutes of MSC-53

MSC/M/53/2017
For adoption

Item 6 – Substance evaluation - Decision making process

Timing: Day 1 - Day 2 for item 6b
Closed session for 6c

- a. Written procedure report on seeking agreement on a draft decision on substance evaluation**

ECHA/MS-54/2017/001
For information

b. Introduction to and preliminary discussion on a draft decision on substance evaluation after MS-CA's/ECHA reactions (*Session 1, open session*):

ECHA/MSC-54/2017/002

For information

For discussion followed by agreement seeking under 6c:

MSC code	Substance name	EC No./Document n:o
SEV-BE-003/2015	1,2,4-triazole	206-022-9 ECHA/MSC-54/2017/005-006
SEV-IT-024/2015	Hexafluoropropene	204-127-4 ECHA/MSC-54/2017/007-008
SEV-IT-026/2015	Di-tert-pentyl peroxide	234-042-8 ECHA/MSC-54/2017/009-010
SEV-NL-029/2015	Tetrapropylenebenzene (benzene, mono-C11-C13- branched alkyl derivatives)	810-801-4 (previously 246-772-4) ECHA/MSC-54/2017/011-012

For discussion

c. Seeking agreement on a draft decision when amendments were proposed by MS-CA's/ECHA (*Session 2, closed*)

Cases as listed above under **6b**

For agreement

Item 7 – Dossier evaluation

***Timing: Day 3 (pm) - Day 4 for item 7b
Closed session for 7c***

a. Written procedure report on seeking agreement on draft decisions on dossier evaluation

ECHA/MSC-54/2017/003

For information

b. Introduction to and preliminary discussion on draft decisions on compliance checks and testing proposals when amendments were proposed by MS-CA's (*Session 1, open session*)

ECHA/MSC-54/2017/004

For information

For discussion followed by agreement seeking under 7c:

Compliance checks

MSC code	Substance name	EC No./Document No.
CCH-020/2017	Butyl glycollate	230-991-7 ECHA/MSC-54/2017/013-014
CCH-021/2017	Acrylic acid, monoester with propane-1,2-diol	247-118-0 ECHA/MSC-54/2017/024-025
CCH-034/2017	Terpineol	232-268-1 ECHA/MSC-54/2017/015-016

c. Seeking agreement on draft decisions on compliance checks and testing proposal examinations when amendments were proposed by MS-CA's (Session 2, closed)

Cases as listed above under **7b**

For agreement

Item 8 – SVHC identification - Seeking agreement on Annex XV proposals
Start of item 8 BPA is Day 1 (am) and PFHxS is Day 3 (pm)

a. Seeking agreement on Annex XV proposals for identification of SVHC

Substance name	EC No.	Document No.
4,4'-isopropylidenediphenol (bisphenol A, BPA)	201-245-8	ECHA/MSC-54/2017/017-019
Perfluorohexane-1-sulphonic acid and its salts (PFHxS)	-	ECHA/MSC-54/2017/020-022

For discussion and agreement

b. Proposal for an update of MSC Working procedures for SVHC identification

ECHA/MSC-54/2017/023

For discussion and possible adoption

Item 9 – Any other business

- Update on appeals and court cases (*partly closed session*)
- Brief report from an *ad-hoc* scoping group meeting on UVCBs
- Suggestions from members

For information

For information

For information

Item 10 – Adoption of main conclusions and action points

- Table with conclusions and action points from MSC-54

For adoption

Information documents

Information documents are not allocated a specific agenda time but the documents are available on MSC CIRCABC before the meeting. Based on the listed documents and the meeting agenda, if any MSC member considers that information documents may merit a discussion under any agenda point, they should inform MSC Secretariat

- Status report on on-going substance evaluation work (presentation slides)
- Preannouncement of substance evaluation workshop (ECHA/MSC/I/2017/014)
- Status report on on-going dossier evaluation work (presentation slides)